caretrace.iopowered by▸healthparse
SearchCohort Builder
Tools▾
KOL FinderTerritoriesDrug Compare
AI Query
Browse▾
By stateBy specialty
Pricing
SearchCohort BuilderToolsKOL FinderTerritoriesDrug CompareAI QueryBrowseBy stateBy specialtyPricing
PROVIDER PROFILE · NPI 1356447486

Steven ShermanM.D.

PRACTICEMDACCSee all providers at this practice →
EndocrinologyHouston, TXI
CROSS-REFERENCE

Related data on other Healthparse brands

ProviderScore
OIG/SAM exclusion screening, sanctions history
© 2026 CareTrace
PricingContactPrivacyTerms
REFERRAL NETWORK

Where Steven Sherman's patients come from & go

Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 2 inbound referrers · 5 outbound destinations.

Receives referrals from
Inbound — who sends patients here
PhysicianPatientsVisits
UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER129694
NPI 12453357103243
Refers patients to
Outbound — where patients go next
PhysicianPatientsVisits
UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER60339
Salmaan Ahmed
Diagnostic Radiology · Houston, TX
1725
Komal Shah
Diagnostic Radiology · Houston, TX
1120
Carol Wu
Diagnostic Radiology · Houston, TX
1117
Patricia De Groot
Diagnostic Radiology · Houston, TX
1122
Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.
MEDICARE UTILIZATION · PART B · 2024
Total beneficiaries
185
Unique beneficiaries
—
Total services
227
Distinct HCPCS
5
Medicare payment
$13K
Peer benchmark
Q1
Q2
Q3
Q4
Q5
Total Medicare services vs. 484 Endocrinology providers in TX — bottom quintile (cohort median 868).
PRESCRIBING · PART D · 2024
Total Rx claims
199
Beneficiaries
—
Total drug cost
$911K
Distinct drugs
6
Brand share
52.3%
Top prescribed drugs
Levothyroxine Sodium72 claims
Levothyroxine Sodium59 claims
Lenvatinib Mesylate22 claims
Cabozantinib S-Malate12 claims
Methimazole12 claims
QUALITY · MIPS · 2024
Final MIPS score
84.3
Quality
70.8
Cost
67.6
Improvement activities
40.0
Promoting interop.
100.0
Payment adjustment
0.39%
Group
INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024
No data available for this provider in 2024.